Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist
about
sameAs
Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically activeP-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociceptionBuprenorphine: a unique drug with complex pharmacologyOpioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individualsCentral mediators involved in the febrile response: effects of antipyretic drugsBuprenorphine - an attractive opioid with underutilized potential in treatment of chronic painA review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceManagement of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technologyThe nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medicationsCholesterol reduction by methyl-beta-cyclodextrin attenuates the delta opioid receptor-mediated signaling in neuronal cells but enhances it in non-neuronal cellsRole of central and peripheral opiate receptors in the effects of fentanyl on analgesia, ventilation and arterial blood-gas chemistry in conscious ratsAn intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-AmericansOn deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical dataSelectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinityTransdermal buprenorphine - a critical appraisal of its role in pain management.BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in miceThe Nociceptin Receptor as an Emerging Molecular Target for Cocaine AddictionBuprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawalBuprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor systemA G protein-coupled receptor (GPCR) in red: live cell imaging of the kappa opioid receptor-tdTomato fusion protein (KOPR-tdT) in neuronal cells.Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphineOligodendrocyte responses to buprenorphine uncover novel and opposing roles of μ-opioid- and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancyCompulsive-like responding for opioid analgesics in rats with extended access.Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.Assessment of an Orofacial Operant Pain Assay as a Preclinical Tool for Evaluating Analgesic Efficacy in RodentsAssessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.Activities of mixed NOP and mu-opioid receptor ligands.Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory painAgonist treatment did not affect association of mu opioid receptors with lipid rafts and cholesterol reduction had opposite effects on the receptor-mediated signaling in rat brain and CHO cellsPlasma concentrations of buprenorphine following a single subcutaneous administration of a sustained release formulation of buprenorphine in sheep.The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphineEvaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal BuprenorphineRegulator of G protein signaling proteins differentially modulate signaling of mu and delta opioid receptors.The effects of repeated opioid administration on locomotor activity: I. Opposing actions of mu and kappa receptors.Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine.Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: potentiation of morphine anti-allodynic activity by NOP receptor antagonists.
P2860
Q24629014-E397F985-6291-4271-8826-21C60B22791FQ24631289-7258403A-11D9-4C33-97BC-26909F643EF6Q24642980-697943AA-186F-4E1C-8F4F-393E2B2EFEEBQ26745747-F2B9A41B-1B70-4361-B4D3-514B3C6B24A5Q26745774-9F5D1DF1-AF1D-4A4D-A678-B2CDD7DA975CQ26775658-0A2BC906-47D3-4F7F-A21A-E3875106ACC5Q27692040-D4B433B2-D3D8-454A-BB7F-787681FCA171Q28080140-2570907E-0068-4B69-A143-66F14CF44B37Q28297686-F2A6F799-28AA-48D8-A3D0-12CCB7B6211EQ28578357-9EDEC6D5-FE14-471E-AAF6-49CC57F1BA99Q30405854-21B7576F-D57D-4069-B237-BD9F3690B15FQ30543145-53D505DF-0FB4-4538-B1B9-0A9B90CEE379Q33522859-33754D0D-C1A7-4562-8C7A-BD91714E7F41Q33662388-7A9D9147-BB93-4534-B57D-D813D74690A2Q34418193-C5F94D4D-BAC8-47E9-9612-29A4CC3EFD62Q34423181-0AB13431-5AE5-4BCA-9124-E72E90C3B499Q34436340-A373EC8E-B64D-40E3-B04F-3D65E5C8EDE5Q34510753-33A1F188-786A-405F-B4DC-841FE7DE6994Q34552092-44D5EB85-FE2F-4363-8349-7BC0C99FC379Q34561447-9E3369C7-C511-4EC2-9D7C-BC7767668FECQ34821230-BCC259D6-7AA9-4774-974D-801DD94BD77DQ35284997-CDE301F4-B662-4160-93E9-99A972999411Q35552420-0F1A6EAE-777C-47BA-8C2A-BF22EF3A1BF3Q35647339-7939562E-4D25-4913-B5BB-9509387063F4Q35863900-4EF2F122-2B41-47BD-B099-4241B42D9D88Q35906905-8103DC41-882B-4C42-8048-61CBDAC8CC51Q35960681-8682CEA9-163A-44C0-AAFD-14FC297D2B46Q36104010-21EC964E-042F-4B98-96BE-BB646188A196Q36296864-E3113F44-8714-4AE2-98FB-6E650816CB17Q36456876-91BA515B-D4A0-455F-A8EE-73D0F5F1D2F8Q36744366-003F5F37-9E27-431E-859E-958D6D2ED874Q36935325-88004902-2C55-41D6-8E76-E630CA9CBE0BQ37024539-C37C478E-8615-4257-97F7-3B03251527C7Q37046077-9888DB7C-C07F-46A1-B269-E7D1978C93D4Q37073555-6565A588-821F-4E70-9341-BFD7089F8E4BQ37173960-5EEDE414-09CE-477A-B735-861482D9C965Q37228167-DDB8D953-4E6F-4B3F-9704-BE61A28F3A48Q37267983-EF8B1A5C-C02B-4E1D-B781-78E014CE1444Q37290396-AA1FE675-A966-44F5-A3E7-592074D1A0DEQ37343674-9F8E97C1-47A0-497E-8896-143A431DDE22
P2860
Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Comparison of pharmacological ...... ine is a potent opioid agonist
@ast
Comparison of pharmacological ...... ine is a potent opioid agonist
@en
Comparison of pharmacological ...... ine is a potent opioid agonist
@nl
type
label
Comparison of pharmacological ...... ine is a potent opioid agonist
@ast
Comparison of pharmacological ...... ine is a potent opioid agonist
@en
Comparison of pharmacological ...... ine is a potent opioid agonist
@nl
prefLabel
Comparison of pharmacological ...... ine is a potent opioid agonist
@ast
Comparison of pharmacological ...... ine is a potent opioid agonist
@en
Comparison of pharmacological ...... ine is a potent opioid agonist
@nl
P2093
P3181
P1476
Comparison of pharmacological ...... ine is a potent opioid agonist
@en
P2093
P304
P3181
P407
P577
2001-05-01T00:00:00Z